TETRAPHASE PHARMACEUTICALS, INC.  Watertown, MA, USA
tphase.com

TP-6076
NEXT-GENERATION TETRACYCLINE

Direct-Acting Small Molecule Therapeutic
Tetraphase Pharmaceuticals uses its proprietary chemistry technology to create novel antibiotics for bacterial infections, including those caused by multidrug-resistant bacteria. The CARB-X collaboration will support the advancement of TP-6076. This Phase 1 drug candidate is a novel, synthetic, fluorocycline antibiotic being developed for the treatment of serious and life-threatening bacterial infections, including those caused by pathogens otherwise resistant to current treatment options. It is highly active against clinically important Gram-negative pathogens, including carbapenem-resistant Acinetobacter baumannii and Enterobacteriaceae. (NASDAQ:TTPH)

Current Development Stage: Phase 1

CARB-X Investment: Investment of up to $4.0m

Initial CARB-X Investment Date: April 1, 2017